2Kopec M, Kucharz EJ. Mixed cryoglobulinemia[J]. Poi Arch Med Wewn, 2001, 106(4): 955-961.
3Zignego AL, Ferri C, Giannelli F, et al. Prevalence of bcl-2 rearrangement in patients with hepatitis C virus-related mixed cryoglobulinemia with or without B-cell lymphomas[J]. Ann Intern Med, 2002, 137(7): 571-580.
4Ferri C, La Civita L, Longombardo G, et al. Mixed cryoglobulinaemia: a cross-road between autoimmune and lymphoproliferative disorders[J]. Lupus, 1998, 7(4): 275-279.
5Dumoulin FL, Klein P, Fischer HP, et al. Chronic hepatitis C in type-Ⅱ cryoglobulinemia and cutaneous vasculitis[J]. Dtsch Med Wochenschr, 1994, 119(37): 1239-1242.
2Arzoo K, Sadeghi S, Liebmao HA. Treatment of refractory aotibody mediated autoimmune disorders with an aoti-CD20 monoclonal aotibody (rituximab). Ann Rheum Dis, 2002, 61: 922-924.
3Keir GJ, Maher TM, Hansell OM, et al. Severe interstitial lung disease in connective tissue disease: rituximab as rescue therapy. Eur RespirJ, 2012, 40: 641-648.
4Zaja F, de Vita S, Mazzaro C, et al. Efficacy and safety of rituximah in type Il mixed cryoglobulinemia. Blood, 2003, 10: 3827-3834.
5De Vita S, Quartuccio L, Fahris M. Rituximah in mixed cryoglobulinemia: increased experience and perspectives. Dig Liver Dis, 2007, 39 Suppl 1: 122-128.
6Ferri C, Cacoub P, Mazzaro C. Treatment with rituximab in patients with mixed cryoglobulinemia syndrome: results of multicenter cohort study and review of the literature. Autoimmun Rev, 2011, 11: 48-55.
